Shutdown, Tariffs, Pharma Pricing Make for a Busy Start to the Quarter. What Matters.
1. Government shutdown may not significantly impact stock market, historically. 2. Trump administration’s drug pricing initiative supports PFE stock despite tariff fears. 3. PFE's $70 billion U.S. investment likely pre-planned, lessening immediate concerns. 4. Consumer drug pricing changes may not help patients' out-of-pocket costs. 5. Tariff threats pose long-term risks to U.S. companies, including PFE.